Annals of Hepatology (Mar 2013)
An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver
- Norberto C. Chávez-Tapia,
- Ezequiel Ridruejo,
- Angelo Alves de Mattos,
- Fernando Bessone,
- Jorge Daruich,
- Juan F. Sánchez-Ávila,
- Hugo Cheinquer,
- Rodrigo Zapata,
- Misael Uribe,
- Francisco Bosques-Padilla,
- Adrián Gadano,
- Alejandro Soza,
- Milagros Dávalos-Moscol,
- Claudio Marroni,
- Linda Muñoz-Espinoza,
- Graciela Castro-Narro,
- Raymundo Paraná,
- Nahum Méndez-Sánchez, MD, MSc, PhD, FACG, AGAF
Affiliations
- Norberto C. Chávez-Tapia
- Liver Research Unit, Medica Sur Clinic & Foundation. Mexico City, Mexico
- Ezequiel Ridruejo
- Hepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno CEDIC, Ciudad Autónoma de Buenos Aires, Argentina
- Angelo Alves de Mattos
- Department of Gastroenterology, Universidade Federal de Ciencias da Saúde de Porto Alegre, Rio Grande do Sul, Brazil
- Fernando Bessone
- División Gastroenterología, Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina
- Jorge Daruich
- Liver Unit, Hospital de Clínicas San Martín, University of Buenos Aires and Gastroenterología Diagnóstica y Terapéutica, Buenos Aires, Argentina
- Juan F. Sánchez-Ávila
- Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México
- Hugo Cheinquer
- Associate Professor of Gastroenterology and Hepatology at Hospital de Clínicas de Porto Alegre (Universidade Federal do Rio Grande do Sul) and Hospital da Santa Casa de Misericórdia de Porto Alegre (Fundação Universidade Federal de Ciências da Saúde de Porto Alegre, Brazil
- Rodrigo Zapata
- Hepatology and Liver Transplant Unit University of Chile School of Medicine, Hospital Salvador. Universidad del Desarrollo, Clínica Alemana. Santiago, Chile
- Misael Uribe
- Liver Research Unit, Medica Sur Clinic & Foundation. Mexico City, Mexico
- Francisco Bosques-Padilla
- Servicio de Gastroenterología, Departamento de Medicina Interna, Hospital Universitario Dr. José Eleuterio González, Nuevo León, Monterrey, México
- Adrián Gadano
- Sección Hepatología, Hospital Italiano, Buenos Aires, Argentina
- Alejandro Soza
- Department of Gastroenterology, Pontificia Universidad Católica de Chile, Marcoleta 367, Casilla 114-D, Santiago, Chile
- Milagros Dávalos-Moscol
- Servicio de Hígado, Hospital Edgardo Rebagliati. Universidad San Martín de Porres. Universidad de Ciencias Aplicadas, Lima, Perú
- Claudio Marroni
- Gastroenterology, Federal University of Health Sciences of Porto Alegre, Rio Grande do Sul, Brazil
- Linda Muñoz-Espinoza
- Facultad de Medicina, Hospital Universitario Dr. José E. González, UANL, Nuevo León, Monterrey, México
- Graciela Castro-Narro
- Liver Research Unit, Medica Sur Clinic & Foundation. Mexico City, Mexico
- Raymundo Paraná
- Gastro-Hepatology Unit, Federal University of Bahia, Brazil
- Nahum Méndez-Sánchez, MD, MSc, PhD, FACG, AGAF
- Liver Research Unit, Medica Sur Clinic & Foundation. Mexico City, Mexico; Correspondence and reprint request:
- Journal volume & issue
-
Vol. 12
pp. S3 – S35
Abstract
Hepatitis C is a common cause of end-stage liver disease, and the main indication for liver transplantation in Latin America. Treatment of hepatitis C infected patients improves important long-term outcomes as mortality. Sustained viral response is reached in near 50% of patients with the previous management based in pegylated interferon and ribavirin. Recently new drugs were available increasing sustained viral response significantly, changing the standard of care to triple therapy. This guidelines provides a framework for practitioner in Latin America, to the management of patients with hepatitis C chronic infection.
